1.11

9.36% 0.095

Tempest Therapeutics Inc (TPST)

Overview News Price History Option Chain Financials Why TPST Down? Discussions Forecast Stock Split

Tempest Therapeutics Inc stock is traded at $1.11, with a volume of 769.32K. It is up +9.36% in the last 24 hours and up +14.91% over the past month. Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Previous Close:

$1.015

Open:

$1.09

24h Volume:

769.32K

Relative Volume:

4.16

Market Cap:

$17.90M

Revenue:

Net Income/Loss:

$-43.10M

P/E Ratio:

-0.1787

EPS:

-6.2098

Net Cash Flow:

$-26.38M

1W Performance:

+6.73%

1M Performance:

+14.91%

6M Performance:

-52.97%

1Y Performance:

-78.92%

1-Day Range:

$1.045

$1.17

1-Week Range:

$0.9942

$1.26

52-Week Range:

$0.8401

$6.115

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name

Tempest Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

415-798-8589

Address

2000 SIERRA POINT PARKWAY, BRISBANE

Employee

Twitter

Next Earnings Date

2026-08-17

Latest SEC Filings

TPST's Discussions on Twitter

Compare TPST vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TPST Tempest Therapeutics Inc	1.12	16.22M	0	-43.10M	-26.38M	-6.2098
VRTX Vertex Pharmaceuticals Inc	516.85	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	808.09	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	989.62	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	214.50	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.27	39.31B	5.76B	514.49M	1.10B	4.4813

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-26	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-10-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Feb-08-24	Initiated	Jefferies	Buy

Tempest Therapeutics Inc Stock (TPST) Latest News

Aug 14, 2026

Tempest Therapeutics Cash Drops to $0.8M Amid Recent Asset Acquisition - Minichart

Aug 14, 2026

Tempest Therapeutics Secures Up to $50 Million Equity Facility From Lincoln Park - Minichart

Aug 14, 2026

Tempest Therapeutics Cash Drops to $0.8 Million, Raising Going-Concern Risk - Minichart

Aug 14, 2026

Aug 13, 2026

Form 8K Tempest Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

Tempest Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Tempest Therapeutics Secures Flexible $50 Million Equity Facility - TipRanks

Aug 13, 2026

Tempest Therapeutics Q2 loss narrows to $5.2m; advances CAR-T pipeline - scanx.trade

Aug 13, 2026

Tempest TherapeuticsEnters $50 Million Common Stock Purchase Agreement With Lincoln Park - TradingView

Aug 13, 2026

Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain - Stock Titan

Aug 13, 2026

Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors - Quiver Quantitative

Aug 13, 2026

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance

Aug 13, 2026

Aug 07, 2026

Tempest Therapeutics Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView

Aug 07, 2026

Aug 02, 2026

Tempest Therapeutics (TPST) Slides to $0.86, Testing Support Near $0.82Positive Gamma - dars.gov.et

Aug 02, 2026

Jul 28, 2026